Mirum Pharmaceuticals’ (MIRM) Market Outperform Rating Reiterated at Citizens Jmp

Citizens Jmp restated their market outperform rating on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a $132.00 price objective on the stock.

Several other research firms have also recently weighed in on MIRM. Weiss Ratings reissued a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a report on Thursday, January 22nd. Evercore set a $126.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, March 4th. HC Wainwright reissued a “buy” rating and set a $130.00 price objective on shares of Mirum Pharmaceuticals in a report on Monday, March 23rd. Royal Bank Of Canada decreased their price objective on shares of Mirum Pharmaceuticals from $130.00 to $128.00 and set an “outperform” rating for the company in a report on Thursday, February 26th. Finally, Morgan Stanley boosted their price objective on shares of Mirum Pharmaceuticals from $95.00 to $123.00 and gave the company an “overweight” rating in a report on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $117.67.

Mirum Pharmaceuticals Stock Down 2.5%

Shares of Mirum Pharmaceuticals stock opened at $91.95 on Tuesday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.55 and a current ratio of 2.67. The stock has a market capitalization of $5.55 billion, a PE ratio of -191.56 and a beta of 0.51. Mirum Pharmaceuticals has a 52-week low of $39.51 and a 52-week high of $109.28. The company has a 50-day simple moving average of $94.78 and a two-hundred day simple moving average of $84.50.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.The firm had revenue of $148.93 million during the quarter, compared to analysts’ expectations of $141.78 million. During the same period last year, the firm posted $1.00 earnings per share. The firm’s quarterly revenue was up 49.8% on a year-over-year basis. On average, analysts anticipate that Mirum Pharmaceuticals will post -1.77 EPS for the current fiscal year.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 40,985 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $91.98, for a total value of $3,769,800.30. Following the completion of the transaction, the chief executive officer directly owned 194,309 shares in the company, valued at $17,872,541.82. This represents a 17.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Jolanda Howe sold 4,732 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $435,249.36. Following the completion of the transaction, the senior vice president owned 8,429 shares of the company’s stock, valued at approximately $775,299.42. The trade was a 35.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 101,382 shares of company stock valued at $9,518,928. Insiders own 14.36% of the company’s stock.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. Cullen Frost Bankers Inc. bought a new position in shares of Mirum Pharmaceuticals during the fourth quarter worth $30,000. MCF Advisors LLC boosted its position in shares of Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after acquiring an additional 185 shares during the last quarter. Eurizon Capital SGR S.p.A. bought a new position in shares of Mirum Pharmaceuticals during the fourth quarter worth $32,000. CIBC Private Wealth Group LLC bought a new position in shares of Mirum Pharmaceuticals during the fourth quarter worth $32,000. Finally, Quantbot Technologies LP bought a new position in shares of Mirum Pharmaceuticals during the third quarter worth $33,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.